Verily

By Laura Lovett March 15, 2019
When it comes to digital health, investors get a bird’s eye view and play a major role in steering the direction of the industry’s future. That is why many are stressing the importance of a diverse viewpoint for investors in an industry focused on bringing digital tools to the masses.  Traditionally this has been a challenge for the venture space, where women only account for 12.2 percent of...
By Laura Lovett February 25, 2019
Google has been busy recently. Just in the past week it has closed down its Google Fit website,  launched a new drug disposal tool and announced the first clinical use of Verily’s machine learning tool for diabetic related diseases.  Below is a look at three of the company’s digital health announcements in the last week.  Addressing the opioid crisis  It started last Wednesday when Google...
By Dave Muoio February 4, 2019
Verily's prototype smart shoe. Verily is shopping for partners to develop a smart shoe with embedded sensors for movement, weight and fall monitoring, according to a CNBC report citing three anonymous sources. The company allegedly has a prototype design of the footwear that it has been showing off in private meetings, and is envisioning the shoe as a health product. … MRIs are A-OK. Senseonics’...
By Laura Lovett January 18, 2019
This morning Alphabet’s life science subsidiary Verily announced that its Verily Study Watch and its on-demand ECG feature landed a 510(k) clearance from the FDA. The watch is a prescription-only device, and was designed to record, store, transfer and display single-channel ECG rhythms. The company said the device’s ability to take on-demand, single-lead ECG can be used for individual patient...
By Laura Lovett January 4, 2019
This morning Alphabet life science subsidiary Verily announced a staggering $1 billion in new venture funding led by Silver Lake, with participation from Ontario Teacher’s Pension Plan and other global investment management firms. As part of the deal, Silver Lake Managing Partner and Director Egon Durban will be nominated to the company’s operating board, as will Ruth Porat, chief financial...
By Dave Muoio December 20, 2018
Alphabet’s business interests cover a wide range of industries, and healthcare is certainly among them. With each passing year, Alphabet (or Google, or Verily) unveils a growing collection of tech-driven partnerships and healthcare tools — read on for a compilation of the company’s news in 2018. January 4: Cityblock Health, the urban-focused public health startup that spun out of Alphabet’s...
By Dave Muoio December 13, 2018
Onduo, a Verily-Sanofi joint venture focused on digitally-driven diabetes management, is looking to further protect its members from foot ulcers and limb loss. Orpyx Medical Technologies’ diabetic foot ulcer sensors for its members. Thanks to a newly announced deal struck between the companies, Orpyx Medical Technologies’ FDA-cleared SurroSense Rx system will be available to “select members” of...
NovioSense's artist conception of its device in use.

NovioSense's artist conception of its device in use.

By Jonah Comstock November 20, 2018
Last week, Alphabet subsidiary Verily Life Sciences announced the end, at least for the foreseeable future, of its glucose-sensing contact lens collaboration with Novartis. Verily CTO Brian Otis gave his thoughts in a blog post at the time, stressing the learnings the company got from the project. In a recent interview with MobiHealthNews, Novartis Global Head of Digital Development Jacob LaPorte...
By Jonah Comstock November 16, 2018
Four years after announcing an ambitious — and often ridiculed — project to create a glucose-sensing contact lens along with Novartis subsidiary Alcon, Alphabet's Verily is throwing in the towel, the company announced in a blog post today. It will continue to work on two other medical contact lens projects, aimed at presbyopia and cataract surgery recovery. "Our clinical work on the glucose-...
FDA Pre-Cert panel at Connected Health Conference

(L to R) Moderator Scott Thiel, Pear Therapeutics' Dan Amor, Verily's Afia Asamoah, Tidepool's Howard Look, and Johnson & Johnson's Eduardo Sanchez (photo by Jonah Comstock)

By Jonah Comstock October 19, 2018
Attendees to the Connected Health Conference in Boston this week got a sneak peek into the workings of the FDA's much-discussed Pre-Cert program. In a panel discussion at the event, representatives from Verily, Pear Therapeutics, Tidepool, and Johnson & Johnson candidly discussed their experiences so far with the program, describing an evolving process that is collaborative and rigorous.  "...